Sunshine Biopharma, Inc. reported a revenue increase of approximately 4% for the fiscal year ending December 31, 2025, generating $36.3 million compared to $34.9 million in 2024. The growth was attributed to expanded sales efforts by its subsidiary, Nora Pharma, across several Canadian provinces, including Quebec, Ontario, Alberta, and British Columbia. Despite the revenue growth, the company incurred a net loss of $5.98 million, a slight increase from the $5.13 million loss reported in the previous year. The cost of sales decreased to $24.05 million, representing 66.2% of revenues, down from 69.4% in 2024, primarily due to lower professional allowances and wholesaler fees.
In terms of operational developments, Sunshine Biopharma continues to focus on its proprietary drug development programs, including K1.1 mRNA for liver cancer and SBFM-PL4, a protease inhibitor targeting SARS Coronavirus. The company has 71 generic prescription drugs currently on the market in Canada and plans to launch an additional 12 drugs by the end of 2026, which will enhance its presence in the Canadian generic drug market valued at approximately $10.4 billion. The company’s workforce remains stable at 50 full-time employees, with no significant changes reported.
The filing also highlighted strategic initiatives aimed at reducing general and administrative expenses, which rose to $18.5 million in 2025 from $16.5 million in 2024. A non-cash impairment charge of $1.75 million related to intangible assets contributed to this increase. Sunshine Biopharma has implemented measures expected to cut expenses by $2 million to $3 million in 2026, although the realization of these savings is uncertain.
Looking ahead, Sunshine Biopharma's liquidity position remains stable with cash and cash equivalents of $9.1 million as of December 31, 2025. The company anticipates that its existing cash will be sufficient to fund operations for the next 18 months, but it acknowledges the need for additional capital to support its growth initiatives. The company has not yet received regulatory approval for its proprietary drug candidates and continues to face challenges in the competitive pharmaceutical landscape, particularly in the generic drug market.
About Sunshine Biopharma, Inc
Sunshine Biopharma Inc. is a pharmaceutical company focused on developing and commercializing generic, OTC, and proprietary medicines across therapeutic areas such as oncology and antivirals. It owns a portfolio of approved generics in Canada, develops novel drug candidates including mRNA-based cancer therapies and coronavirus inhibitors, and seeks to expand its market presence through licensing, licensing agreements, and strategic partnerships. The company emphasizes innovation, regulatory compliance, and competitive positioning in global markets.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.